ClinicalTrials.gg
CompletedNCT06367712Updated Apr 16, 2024

Letrozole Alone Protocol Versus Using Letrozole and HCG Protocol

A Phase 1 interventional study of Letrozole tablets in PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, sponsored by Egymedicalpedia. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2024-04-16.

Sponsored by Egymedicalpedia · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Nov 2022, registered Apr 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing letrozole in Polycystic Ovary Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. Letrozole · Polycystic Ovary Syndrome.

Enrollment
14th of 26
132 · median 139
Started
2022
the only one that year
Phase 1
3 of 26
none open now
Registered
18th of 26
by date
Lead sponsor
2 of 26
Egymedicalpedia

Among the 26 studies testing letrozole in Polycystic Ovary Syndrome, this one is the 14th largest by enrollment, is the only one that started in 2022, is one of 3 in phase 1, and was the 18th registered.

Polycystic Ovary Syndrome

958 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

1 of the 26 studies testing letrozole in Polycystic Ovary Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 119 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 105 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing letrozole in Polycystic Ovary Syndrome, or all of them as a file.
02

Study summary

Letrozole is a chemical compound, CGS 20267 which is a third-generation, nonsteroidal aromatase inhibitor.

Letrozole blocks estrogen synthesis by directly affecting the hypothalamic-pituitary-ovarian axis, subsequently, increases gonadotropins which increase pregnancy rates. Possible positive outcomes of aromatase inhibitors over selective estrogen-receptor modulators include a more physiologic hormonal stimulation of the endometrium which increases receptivity, a lower multiple-pregnancy through single follicle growth, a lesser side-effect especially vasomotor and mood symptoms, and more prompt clearance from blood, hence, reducing the probabilities of periconceptional exposure

Read the detailed description

The first pilot study for the clinical use of letrozole for ovarian induction in polycystic ovary syndrome (PCOS) patients was done in 2000.

In large randomized study, letrozole was superior to clomiphene as a treatment for anovulatory infertility in women with the polycystic ovary syndrome. Letrozole was also associated with higher live-birth and ovulation rates.

Ovulation induction with letrozole is associated with an ovulation rate of 70%-84% and a pregnancy rate of 20%-27% per cycle.

While in another study which Compare the Effect of Letrozole Alone with Letrozole Plus N-Acetylcysteine on Pregnancy Rate in Patients with Polycystic Ovarian Syndrome, the pregnancy rate was 7.5% in letrozole alone group .

Human chorionic gonadotropin (HCG) hormone will replace the naturally surging luteinizing hormone at mid-cycle, subsequently, will lead to full maturation of oocytes resulting in ovulation. Additionally, HCG will also enhance the endometrial quality by stimulating the corpus luteum. HCG is a hormone that is produced mainly by the placental syncytiotrophoblasts cells, it is also produced by other organs in minute amounts (Liver, colon and pituitary gland). HCG main function is maintaining pregnancy through stimulating the corpus luteum to produce progesterone.

This hormone is the cornerstone drug for inducing final maturation of follicles during a diversity of infertility treatment protocols.

In order to diagnose Polycystic ovarian syndrome two out of three Rotterdam criteria should be present. These criteria are: chronic anovulation, clinical and/or biochemical evidence of hyperandrogenism, and polycystic ovaries by ultrasound .

incidence of PCOS from 6% to 21% when the ESHRE/ASRM 2003 criteria were applied. Infertility (clinical definition) is currently defined as 1 year of unwanted non-conception with unprotected intercourse in the fertile phase of the menstrual cycles

03

Conditions studied

  • PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infertile women with PCOS
  • Normal hysterosalpingography
  • Normal semen analysis according to WHO parameters are major prerequisites

Exclusion criteria

Exclusion Criteria:

  • Infertile women with causes other than PCOS,
  • Ages \<18 or >35 years
  • women taken confounding medications like other infertility drugs
  • Insulin sensitizers or hormones
  • Abnormal hysterosalpingography
  • Subnormal semen analysis
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
132 participants (actual)

Study arms

  • Active comparator
    Group A: letrozole only

    About 66 Patients took Letrozole drug only for induction of ovulation at the time of suspected ovulation maturity.

    Drug: Letrozole tablets

  • Active comparator
    Group B: letrozole + HCG

    About 66 Patients took Letrozole drug in addition to HCG for induction of ovulation at the time of suspected ovulation maturity.

    Drug: Letrozole tablets

Interventions

  • To determine if the usage of All interventions are effective for simple induction of ovulation in polycystic ovarian syndrome in infertile couples.

    Also known as: HCG

06

What researchers measure

Primary outcomes

  1. Pregnancy test

    The participants required to make pregnancy test after taking the drugs of the study

    Time frame: 2 weeks after ovulation

07

Study locations

1 site
  • Ahmed Maher Teaching Hospital
    Cairo, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Nov 2023, 11 months.

Of 27 phase 1 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 147. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2024
First posted
Apr 16, 2024
StartActual
Nov 10, 2022
Primary completionActual
Nov 1, 2023
CompletionActual
Nov 10, 2023
Last update
Apr 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06367712
Lead sponsor
Egymedicalpedia
Responsible party
Sponsor
First posted
Apr 16, 2024
Start date
Nov 10, 2022
Primary completion
Nov 1, 2023
Completion
Nov 10, 2023
Last update
Apr 16, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion